SXTC: SXT Pharmaceuticals Market Cap to Revenue

Corporate company logo of SXT China (SXTC)

China SXT Pharmaceuticals (SXTC) maintains a closed-loop production cycle for Chinese medicine, controlling the entire pipeline from fields to pharmacies. This P/S chart for the company on GURU.Markets illustrates the market valuation, where the value of 0.30 expresses the metric level. Flexible raw material outsourcing through cooperatives minimizes risks, while moderate pricing power within the generics niche curbs excessive markup growth.

SXTC: SXT China P/S Multiple 07/04/2022 - 11/15/2026

Analytical breakdowns for sxtchina.com (SXTC)

- market capitalization information:
Summary company analytics:China SXT Pharmaceuticals, SXTC
Manufactured products of China SXT Pharmaceuticals

Investors are assessing the resilience of China SXT Pharmaceuticals (SXTC) through the ratio of the business's market value to its annual turnover. This price-to-sales metric measures how many dollars of capitalization are attributed to each unit of revenue, allowing for a determination of the premium paid for the stable sales of traditional herbal medicines. Analysis of this chart helps determine whether the current undervaluation of shares is a result of market risk or a hidden entry opportunity.

Competitors of China SXT Pharmaceuticals

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)